Development Of Intestinal Dysbiosis Research Articles

Role of the gut microbiota in aging and maintenance of active longevity. Part 1

The role of intestinal microbiota in aging and maintaining active longevity is considered. The first part of the article describes the characteristics of a healthy microbiome, its changes during aging, and the composition of the intestinal microbiome of centenarians. The importance of high microbiome biodiversity in maintaining active longevity is emphasized. The role of intestinal permeability and new biomakers that assess its condition (including zonulin) in maintaining health and in the development of intestinal dysbiosis is revealed. Separate groups of microorganisms that are associated with longevity have been identified (such as Verrucomicrobia, which includes Akkermansia), and the important role of the Bacteroidetes – Firmicutes ratio has been noted. The influence of age-associated changes in the microbiome on health, the connection between changes in the microbiome and physical activity, the possibility of using microbiome analysis to predict biological age, and the correlation of microbiome composition with biomarkers of health and disease are discussed.

Medicinal-microbial interactions and ways of correcting iatrogenic intestinal dysbiosis

The review presents up-to-date information on the pathogenesis of disorders of the intestinal microbiotope and the relationship of these disorders with the use of medications traditionally prescribed in treatment regimens for various diseases, presents the main aspects of drug-microbial interactions, highlights the issues of correction of iatrogenic intestinal dysbiosis. One of the main exogenous factors in the development of intestinal dysbiosis at the present time, of course, can be considered drug therapy. The extremely widespread and often uncontrolled use of antibacterial drugs, nonsteroidal anti-inflammatory drugs, laxatives, drugs for the correction of carbohydrate metabolism, proton pump inhibitors, glucocorticosteroids, antidepressants, cytostatic drugs to a greater or lesser extent has a negative effect on the human microbiotope. On the one hand, the microbiota is a drug target, on the other hand, the gut microbiota itself can have both direct and indirect effects on the metabolism of drugs. The potential of the influence of microorganisms on the absorption, distribution, and metabolism of drugs deserves increased attention and detailed study. At the same time, the issues of prevention and correction of intestinal microbiota disorders against the background of taking various medications deserve even more attention from doctors of various profiles with the mandatory inclusion of drugs that harmonize the intestinal microbiotope in the treatment regimens of the underlying disease.

Метаболічно-асоційована жирова хвороба печінки та мікробіота кишечника: патогенетичні взаємозв’язки та терапевтичні мішені

The article presents the characteristics of metabolically associated fatty liver disease (МАFLD) in combination with intestinal microbiota. The risk factors for the development of МАFLD, the importance of the «microbiotaintestine-liver» axis in the progression of fatty liver disease and in the disruption of the intestinal microbiome with the development of intestinal dysbiosis, which leads to metabolic disorders in the body, are revealed. The use of the drug UDHА (Ursis) and coloprotector Zafacol 3D, which are means of pathogenetic therapy in patients with МАFLD and intestinal dysbiosis, is pathogenetically justified.

Gut and airway microbiota and their role in COVID-19 infection and pathogenesis: a scoping review.

BackgroundThe SARS-CoV-2 virus is responsible for the COVID-19 pandemic. Researchers have been studying the pathogenesis of the virus with the aim to improve our current diagnosis and management strategies. The microbiota have been proposed to play a key role in the pathogenesis of the disease.PurposeTo investigate and report on the current available evidence on any associations between the gut and/or airway microbiota and the pathogenesis of COVID-19.MethodsUsing a predefined protocol in compliance with the PRISMA guidelines, a search was conducted on MEDLINE, Science Direct, DOAJ and Cochrane databases on primary research studies assessing the association between COVID-19 infection and the gut and/or airway microbiota.ResultsTwenty-two studies were included in the current review; nineteen studies concluded an association between the gut and/or airway dysbiosis and SARS-CoV-2, while 3 studies failed to observe a significant association between the airway microbiome and SARS-CoV-2 infection. Specifically, most studies reported a decrease in microbial diversity and therefore development of intestinal dysbiosis in COVID-19-positive patients compared to healthy controls as well as a possible association between increased intestinal dysbiosis and disease severity.ConclusionDuring infection with SARS-CoV-2, there are significant changes in the composition of the gut and airway microbiota. Furthermore, the gut microbiota may have a more important role than the airway microbiota in COVID-19 infection. In the future, studies should be more carefully designed to derive more conclusive evidence on the role of the gut and airway microbiota following infection with SARS-CoV-2 which will lead to the formulation of better management strategies in combating COVID-19.Supplementary InformationThe online version contains supplementary material available at 10.1007/s15010-021-01715-5.

<i>Helicobacter pylori</i> infection and inflammatory bowel diseases

Helicobacter pylori is detected in the human intestine on average in 35% of clinical cases, but the question about its etiopathogenetic role in intestinal diseases has not been fully investigated. Many scientists study a relationship between the H. pylori persistence and development of various bowel diseases. Diverse viewpoints have been proposed regarding a potential link between H. pylori and inflammatory bowel diseases (IBD). Here we review the data from domestic and foreign studies aimed at examining potential role of H. pylori both as a trigger and protector resulting in the pathogenetic alterations leading to developing Crohn‘s disease and ulcerative colitis. The former is favored by the hypothesis wherein H. pylori may trigger IBD due to potential connection between extragastric infection and its direct damaging action as well as indirect effects contributing to the initiation of oxidative stress, autoimmune aggression and development of intestinal dysbiosis. In addition, the effects of enterohepatic Helicobacter spp. promoting IBD pathogenesis are discussed. The mechanisms underlying the protective role of H. pylori infection may be driven via differentially expressed acute and/or chronic local inflammatory mucosal response able to downmodulate systemic immune responses and suppress autoimmune reactions, as well as skewing host immune response from a pro-inflammatory Th1/Th17 cell-mediated towards regulatory T-cell response. Moreover, it was found that H. pylori may induce production of antibacterial peptides counteracting potentially pathogenic bacteria involved in IBD pathogenesis. In particular, it was found that IBD patients are dominated with moderate active antral gastritis coupled to atrophy, with the peak intensity observed in patients under 30 years of age. Intensity of intestinal metaplasia in the gastric mucosa of IBD patients accounted for by the duration of the disease course. Basal IBD therapy with 5-aminosalicylic acid lowers severity and activity of gastritis, degree of atrophy as well as magnitude H. pylori invasion in the gastric mucosa. There is evidence that 5-aminosalicylic acid-containing drugs may result in a so-called “spontaneous eradication” of H. pylori infection. Extended investigations are required to examine a role of H. pylori in IBD pathogenesis.

Effect of Dietary Magnesium Content on Intestinal Microbiota of Rats.

Background: Magnesium is a mineral that modulates several physiological processes. However, its relationship with intestinal microbiota has been scarcely studied. Therefore, this study aimed to assess the role of dietary magnesium content to modulate the intestinal microbiota of Wistar male rats. Methods: Rats were randomly assigned one of three diets: a control diet (C-Mg; 1000 mg/kg), a low magnesium content diet (L-Mg; 60 mg/kg), and a high magnesium content diet (H-Mg; 6000 mg/kg), for two weeks. After treatment, fecal samples were collected. Microbiota composition was assessed by sequencing the V3–V4 hypervariable region. Results: The C-Mg and L-Mg groups had more diversity than H-Mg group. CF231, SMB53, Dorea, Lactobacillus and Turibacter were enriched in the L-Mg group. In contrast, the phyla Proteobacteria, Parabacteroides, Butyricimonas, and Victivallis were overrepresented in the H-Mg group. PICRUSt analysis indicated that fecal microbiota of the L-Mg group were encoded with an increased abundance of metabolic pathways involving carbohydrate metabolism and butanoate metabolism. Conclusion: Dietary magnesium supplementation can result in intestinal dysbiosis development in a situation where there is no magnesium deficiency. Conversely, low dietary magnesium consumption is associated with microbiota with a higher capacity to harvest energy from the diet.

The overall structure of microbiota in patients with adenocarcinoma stomach and colon cancer

IntroductionAccumulating evidence suggests that the human bowel microbiota contributes to the etiology of colorectal cancer (CRC) and stomach cancer, not only via the pro-carcinogenic activities of specific pathogens but also via the influence of the wider microbial community, particularly its metabolome.The aim of the studyThe aim of this study was to analyzes the overall structure of microbiota in patients with adenocarcinoma of colorectal and the stomach and healthy controls.ResultsThe studies suggested that colorectal cancer and stomach cancer develops from the complex interactions between inherited susceptibility and environmental factors, there a strong association between adenomatous polyps and some pathogenic bacteria are the precursors of the vast majority of colorectal cancers and stomach. Thus, the data suggested the development of intestinal dysbiosis in patients with adenocarcinoma, which was characterized by inhibiting obligate protective microflora and activation opportunistic microorganisms on the base of carbohydrates, fats, and proteins metabolism disturbances and accumulation of toxic metabolic products that may be an important pathogenetic factor of tumor tissue activation, induction, proliferation, and metaplasia. Significant accumulation of biogenic amines (methylamine, serotonin, histamine) is a leading metabolic profile of microflora inpatient with adenocarcinoma and may have a predictive value for diagnosis, pathogenetic therapy, and determination of food nutrients role in the mechanisms of cancer formation, as well as identifying populations of cancer risk.ConclusionsThe composition of the tumor microbiome differed from that of adjacent non-neoplastic tissue. The subsite-specific alterations in the colorectal carcinoma and stomach cancer microbiota. There is a high incidence of colorectal cancer and stomach cancer associated with Streptococcus Bovis. These results suggested that the mucosa-associated microbiota is dynamically associated with colorectal carcinoma, which may provide evidence for microbiota-associated diagnostic, prognostic, preventive, and therapeutic strategies for colorectal carcinoma and stomach cancer.

ASSOCIATION OF INTESTINAL BACTERIAL OVERGROWTH AND DISEASES OF HEPATOBIARY TRACT

The aim. Find out the nature of the changes of the hepatobiliary system in patients with intestinal bacterial overgrowth and study the possible mechanisms of their association.Materials and methods. 148 patients with intestinal bacterial overgrowth and intestinal dysbiosis were examined. The level of total cholesterol, cholestasis and cytolysis markers was determined in the blood using the analyzer «Labsystems» (Finland). Intestinal bacterial overgrowth syndrome was assessed using a hydrogen breath test with lactulose on the LactophaH2 apparatus of AMA (St. Petersburg). Intestinal dysbiosis was determined by plating feces on nutrient media. Bile acids in bile were determined on the AmazonX mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany). Ultrasound examination of the abdominal cavity performed with the apparatus «SHIMADZU SDN-500» (Japan). Liver elastography was performed using the AIXPLORER apparatus (France).Results. The syndrome of intestinal bacterial overgrowth in 67% of cases was established in the presence of ileocecal insufficiency, in 33% of cases — with preserved ileocecal function. The combination of intestinal bacterial overgrowth syndrome and intestinal dysbiosis was detected in 81,8% of patients. The majority of the examined patients showed clinical symptoms of damage the hepatobiliary system and intestines, which was confirmed by change laboratory parameters — increase the level of total cholesterol, markers of cholestasis and cytolysis compared with the control group. In the study of bile acids in bile, decrease free (mainlycholic) and increase conjugated (glycodesoxycholic, taurodesoxycholic, glycocholic, taurocholic) bile acids was observed compared with the control group. In general, patients with the syndrome of intestinal bacterial overgrowth revealed the presence of non-calculous cholecystitis — in 11,5% of cases, I stage of cholelithiasis — in 25,7%, II stage of cholelithiasis — in 18,9%, non-alcoholic fatty liver disease on stage steatosis and steatohepatitis — in 43,9% of cases.Conclusion. Intestinal bacterial overgrowth syndrome is the beginning of bacterial translocation, which is the triggering factor in inflammation of the liver and biliary tract. In turn, diseases of the hepatobiliary system contribute to the development of intestinal dysbiosis by reducing the synthesis of bile acids with antibacterial action, as well as violations of their excretion. Thus, strong association of intestinal bacterial overgrowth syndrome with damage to the hepatobiliary system has been established.

Common diseases of gerbils

Gerbils are members of the subfamily Gerbillinae, family Muridae, with the Mongolian gerbil (Meriones unguiculatus) being the most common pet species of gerbil available in the UK; they originate from desert regions. Gerbils come in various colourations and are highly social, nocturnal species, creating elaborate underground burrowing systems. While active, they are easily handled and can make good pets. Gerbils are medically more robust than some other rodent species commonly kept as pets; nevertheless there are a number of diseases that are seen in pet gerbils, and the veterinary surgeon should be aware of these. A number of antibiotics have been associated with development of intestinal dysbiosis and fatal enterotoxaemia in gerbils, and their use should be avoided.

Autoprobiotics as an Approach for Restoration of Personalised Microbiota.

Human microbiota is a complex consortium of microorganisms involved in the proper functioning of almost every system of the organism. Majority of the human diseases are associated with the development of intestinal dysbiosis. Dysbiotic condition or dysbiosis is a key pathogenic condition causing many severe infectious or non-infectious diseases. Rapid return to the original microbiota in many cases leads to the fast recovery from the disease. However, the optimal way of the treatment of dysbiosis is still under the discussion. Recently we have developed a method of autoprobiotics based on using isolated indigenous bacteria for improving of microbiota condition. The method based on feeding the patients with bacterial products grown from their personal, genetically characterised strains have been successfully tested in clinic on patients with IBS or chronic pneumonia. In present study we tried to evaluate technology employing autoprobiotic bacteria belonging to different species employing the rat model of antibiotic induced dysbiosis. Six experimental groups of animals after taking antibiotics were treated with different variants of autoprobiotics (lactobacillus, bifidobacteria, enterococcus, their mixture, fecal microbiota, or anaerobically grown complex of indigenous microbiota) prepared for each of them before the development of dysbiosis. Judging by the multiple parameters including metagenomics analysis of microbiota, immune status and microbiota content of the animals with dysbiosis relatively to control group, the most pronounced positive changes were provided by autoprobiotics based on enterococci, bifidobacteria or the consortium of indigenous bacteria grown under anaerobic conditions. These groups of autoprobiotics were delivering the most effective restoration of the original microbiota content and significant anti-inflammatory reaction of the immune system.

The long-term functional consequences of acute infectious diarrhea.

The study reviews recent publications that build on previous studies showing that acute enteric infection can produce persistent dysfunction in the lower gut (postinfectious irritable bowel syndrome) and proximal gut (postinfectious functional dyspepsia). The review addresses risk factors, the pathophysiological basis of persistent gut dysfunction, and the factors that initiate and maintain it. Recent work has identified several loci of host genetic predisposition to these syndromes that focus attention on host immune responses that may lead to gut dysfunction, including changes in intestinal barrier function and cytokine responses to the initial infection. Human and animal studies identify changes in the serotonergic and cannabinoid pathways regulating visceral pain responses and gut motility. Recent work has also focused attention on the putative role of the intestinal microbiota or dysbiosis in maintaining gut dysfunction and this is reviewed in depth. The development of long-term consequences following an acute episode of gastroenteritis reflects a convergence of host factors that include genetic predisposition and psychological factors, as well as the development of intestinal dysbiosis. It is anticipated that future research will generate biomarkers of susceptibility as well as novel microbiota-directed preventive and therapeutic strategies.